All Companies

GILD

Gilead Sciences Inc

Biological Products, (No Diagnostic Substances)

$150.11updated Sep 19, 2026

Congressional trading profile for Gilead Sciences Inc (GILD), covering 17 disclosed transactions by 9 lawmakers.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Total Trades

17

Politicians Trading

9

Last Traded

Aug 10, 2026

Price history

Congressional Trades

PoliticianNotifiedTradedTypeAmountChange
Ro KhannaDSep 4, 2026Aug 10, 2026Sell$1,001 - $15,000+12.81%
Ro KhannaDAug 7, 2026Jul 20, 2026Buy$1,001 - $15,000+12.69%
Ro KhannaDAug 7, 2026Jul 7, 2026Sell$1,001 - $15,000+10.08%
Alan ArmstrongRJul 21, 2026Mar 27, 2026Buy$1,001 - $15,000+11.81%
Jared MoskowitzDJun 19, 2026May 6, 2026Buy$1,001 - $15,000+10.13%
Jared MoskowitzDJun 19, 2026May 6, 2026Buy$1,001 - $15,000+10.13%
Josh GottheimerDFeb 26, 2026Jan 27, 2026Buy$1,001 - $15,000+6.48%
Val T. HoyleDOct 10, 2025Sep 23, 2025Sell$1,001 - $15,000+31.22%
Jefferson ShreveRJun 22, 2025May 12, 2025Sell$15,001 - $50,000+44.59%
Marjorie Taylor GreeneRJun 18, 2025Jun 6, 2025Buy$1,001 - $15,000+33.48%
Josh GottheimerDJun 11, 2025May 14, 2025Sell$1,001 - $15,000+52.58%
John BoozmanRMay 14, 2025Apr 16, 2025Sell$1,001 - $15,000+43.13%
Marjorie Taylor GreeneRMay 6, 2025May 5, 2025Buy$1,001 - $15,000+46.01%
Marjorie Taylor GreeneRMay 6, 2025May 5, 2025Buy$1,001 - $15,000+46.01%
Jefferson ShreveRApr 11, 2025Mar 31, 2025Buy$15,001 - $50,000+33.97%
Carol D. MillerRApr 11, 2025Mar 10, 2025Buy$1,001 - $15,000+28.07%
Josh GottheimerDApr 10, 2025Mar 7, 2025Buy$1,001 - $15,000+27.85%